MCID: ERY003
MIFTS: 60

Erythema Multiforme

Categories: Rare diseases, Skin diseases

Aliases & Classifications for Erythema Multiforme

MalaCards integrated aliases for Erythema Multiforme:

Name: Erythema Multiforme 12 76 53 37 55 15 73
Erythema Polymorphe, Erythema Multiforme Type 53
Dermatostomatitis, Erythema Multiforme Type 53
Herpes Iris, Erythema Multiforme Type 53
Febrile Mucocutaneous Syndrome 53
Erythema Multiforme Bullosum 53
Stevens-Johnson Syndrome 73
Em 53

Classifications:



External Ids:

Disease Ontology 12 DOID:0050185
KEGG 37 H01695
ICD10 33 L51
UMLS 73 C0014742

Summaries for Erythema Multiforme

NIH Rare Diseases : 53 Erythema multiforme (EM) refers to a group of hypersensitivity disorders characterized by symmetric red, patchy lesions, primarily on the arms and legs. The cause is unknown, but EM frequently occurs in association with herpes simplex virus, suggesting an immunologic process initiated by the virus. In half of the cases, the triggering agents appear to be medications, including anticonvulsants, sulfonamides, nonsteroidal anti-inflammatory drugs, and other antibiotics. In addition, some cases appear to be associated with infectious organisms such as Mycoplasma pneumoniae and many viral agents. Erythema multiforme is the mildest of three skin disorders that are often discussed in relation to each other. It is generally the mildest of the three. More severe is Stevens-Johnson syndrome. The most severe of the three is toxic epidermal necrolysis (TEN).

MalaCards based summary : Erythema Multiforme, also known as erythema polymorphe, erythema multiforme type, is related to cervicitis and fixed drug eruption. An important gene associated with Erythema Multiforme is DSP (Desmoplakin), and among its related pathways/superpathways are PEDF Induced Signaling and Cytokine Signaling in Immune system. The drugs Capecitabine and Tirofiban have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and breast, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A skin disease that is a type of allergic reaction located in skin, which occurs in response to medications, infections, or illness.

Wikipedia : 76 Erythema multiforme (EM) is a skin condition of unknown cause; it is a type of erythema possibly... more...

Related Diseases for Erythema Multiforme

Diseases related to Erythema Multiforme via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 302)
# Related Disease Score Top Affiliating Genes
1 cervicitis 30.5 CD79A IL2
2 fixed drug eruption 30.4 IFNG IL2
3 bullous pemphigoid 30.3 CCL17 CD79A DSP
4 chronic graft versus host disease 30.2 CD79A IFNG
5 cytomegalovirus infection 30.2 ICAM1 IFNG TNF
6 myocarditis 30.2 DSP ICAM1 TNF
7 sporotrichosis 30.0 CD79A IFNG
8 vasculitis 29.9 CD79A ICAM1 TNF
9 myeloma, multiple 29.9 CD79A IL2 TNF
10 chlamydia 29.8 CD79A IFNG TNF
11 hematopoietic stem cell transplantation 29.7 IFNG IL2 TNF
12 smallpox 29.7 IFNG IL2 TNF
13 reactive arthritis 29.6 CD79A IFNG TNF
14 colitis 29.6 IFNG IL2 TNF
15 tetanus 29.5 CD79A IFNG IL2
16 lymphopenia 29.4 FASLG IFNG IL2
17 cutaneous lupus erythematosus 28.6 CXCR3 GZMB ICAM1 TNF
18 graft-versus-host disease 28.6 FASLG GZMB IFNG IL2 TNF
19 contact dermatitis 28.4 CCL17 CXCR3 ICAM1 IFNG TNF
20 pulmonary fibrosis, idiopathic 28.3 CCL17 CXCR3 DSP FASLG IFNG TNF
21 rheumatoid arthritis 28.3 CD79A ICAM1 IFNG IL2 TNF
22 allergic contact dermatitis 28.0 CCL17 CXCR3 ICAM1 IFNG TNF
23 acute graft versus host disease 28.0 FASLG GZMB IFNG IL2 TNF
24 lichen planus 27.9 CXCR3 GZMB ICAM1 IFNG TNF
25 autoimmune disease 27.5 CD79A CXCR3 IFNG IL2 TNF
26 skin disease 27.5 CCL17 CD79A DSP ICAM1 IFNG TNF
27 keratoconjunctivitis 27.4 CCL17 CD79A ICAM1 IFNG IL2 TNF
28 lymphadenitis 27.4 CXCR3 FASLG ICAM1 IFNG TNF
29 psoriasis 27.0 CCL17 CXCR3 ICAM1 IFNG IL2 TNF
30 dermatitis, atopic 26.7 CCL17 CXCR3 ICAM1 IFNG IL2 TNF
31 systemic lupus erythematosus 26.5 CD79A CXCR3 FASLG ICAM1 IFNG IL2
32 erythema multiforme major 12.4
33 eosinophilia-myalgia syndrome 12.0
34 epileptic encephalopathy, early infantile, 3 11.2
35 epileptic encephalopathy, early infantile, 4 11.2
36 severe cutaneous adverse reaction 11.2
37 erythromelalgia 11.1
38 pseudomembranous conjunctivitis 11.1
39 pulmonary embolism 11.0
40 encephalopathy, ethylmalonic 10.9
41 alpha-1-antitrypsin deficiency 10.9
42 oral tuberculosis 10.8 IL2 TNF
43 streptococcal toxic-shock syndrome 10.7 IL2 TNF
44 toxicodendron dermatitis 10.7 ICAM1 IL2
45 burning mouth syndrome 10.7 IL2 TNF
46 actinic prurigo 10.7 ICAM1 TNF
47 lymphangiosarcoma 10.6 DSP TNF
48 rheumatoid vasculitis 10.6 ICAM1 TNF
49 arthus reaction 10.6 ICAM1 TNF
50 heterophyiasis 10.6 CD79A ICAM1

Comorbidity relations with Erythema Multiforme via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease

Graphical network of the top 20 diseases related to Erythema Multiforme:



Diseases related to Erythema Multiforme

Symptoms & Phenotypes for Erythema Multiforme

GenomeRNAi Phenotypes related to Erythema Multiforme according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.28 GZMB ICAM1 IL2 TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.28 FASLG GZMB ICAM1 IL2 TNF

MGI Mouse Phenotypes related to Erythema Multiforme:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.02 FASLG ICAM1 CCL17 IFNG CD79A IL2
2 cardiovascular system MP:0005385 9.95 TNF FASLG ICAM1 IFNG CXCR3 IL2
3 hematopoietic system MP:0005397 9.86 TNF FASLG ICAM1 CCL17 IFNG CD79A
4 digestive/alimentary MP:0005381 9.8 TNF FASLG ICAM1 IFNG IL2 DSP
5 immune system MP:0005387 9.76 TNF FASLG ICAM1 CCL17 IFNG CD79A
6 liver/biliary system MP:0005370 9.35 TNF FASLG IFNG CD79A IL2
7 neoplasm MP:0002006 9.17 FASLG ICAM1 IFNG CD79A IL2 CXCR3

Drugs & Therapeutics for Erythema Multiforme

Drugs for Erythema Multiforme (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 758)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 154361-50-9 60953
2
Tirofiban Approved Phase 4,Not Applicable 144494-65-5 60947
3
Ticlopidine Approved Phase 4,Phase 3,Phase 2,Not Applicable 55142-85-3 5472
4
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
5
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Not Applicable 120202-66-6, 113665-84-2 60606
6
Menthol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 2216-51-5 16666
7
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
8
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
9
Metformin Approved Phase 4,Phase 2,Phase 3 657-24-9 14219 4091
10
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 498142 38904
11
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 169590-42-5 2662
12
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 9005-49-6 772 46507594
13 Trapidil Approved Phase 4 15421-84-8
14
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 1 73590-58-6 4594
15
Benzoyl peroxide Approved Phase 4,Phase 3 94-36-0 7187
16
Ephedrine Approved Phase 4 299-42-3 9294
17
Pantoprazole Approved Phase 4 102625-70-7 4679
18
Pseudoephedrine Approved Phase 4 90-82-4 7028
19
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-78-2 2244
20
Abciximab Approved Phase 4,Phase 2,Phase 3 143653-53-6
21
Bivalirudin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 128270-60-0 16129704
22
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
23
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
24
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
25
Chromium Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7440-47-3 27668
26
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 50-24-8 5755
27
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
28
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 159351-69-6 6442177
29
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
30
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 104987-11-3 445643 439492
31
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 55-56-1 9552079 2713
32
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 184475-35-2 123631
33
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
34
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 180288-69-1 9903
35
Ethanol Approved Phase 4,Phase 2,Not Applicable 64-17-5 702
36
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
37
Cilostazol Approved, Investigational Phase 4,Not Applicable 73963-72-1 2754
38
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 83-43-2 6741
39
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
40
Desonide Approved, Investigational Phase 4,Phase 3 638-94-8 5311066
41
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1 51-21-8 3385
42
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
43
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53123-88-9 5284616 6436030 46835353
44
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 56420-45-2 41867
45
Fluticasone Approved, Experimental, Investigational Phase 4 90566-53-3 62924
46
Coal tar Approved Phase 4,Phase 3,Phase 2,Phase 1 8007-45-2
47
Zinc Approved, Investigational Phase 4,Phase 2 7440-66-6 23994
48
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4,Not Applicable 439-14-5 3016
49
Simvastatin Approved Phase 4,Phase 1 79902-63-9 54454
50
Warfarin Approved Phase 4,Phase 1 81-81-2 6691 54678486

Interventional clinical trials:

(show top 50) (show all 3933)
# Name Status NCT ID Phase Drugs
1 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer SES Safety and Effectiveness in CAD Treatment Unknown status NCT01880879 Phase 4
2 Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen Unknown status NCT01267734 Phase 4 Triple anti-platelet therapy (TAT);Double-dose clopidogrel anti-platelet therapy (DDAT)
3 Zotarolimus and Everolimus-Eluting Stents ProsPectively Compared in Real World Unknown status NCT00768846 Phase 4
4 Effect of Fluticasone Proprionate 0.05% on Narrow Band UV-B in Active Vitiligo Unknown status NCT01246921 Phase 4 Fluticasone proprionate 0.05% cream
5 CYPRESS - CYPHER for Evaluating Sustained Safety Unknown status NCT00954707 Phase 4 Clopidogrel & Aspirin, Prasugrel & Aspirin;Placebo & Aspirin
6 Efficacy and Safety of Xience in Coronary arEry Disease aLL-comers After stENTing Using the PRIME Platform (EXCELLENT-PRIME Registry) Unknown status NCT01605721 Phase 4
7 Effects of Celecoxib On Restenosis After Coronary Intervention and Evolution of Atherosclerosis Trial Unknown status NCT00500279 Phase 4 Celecoxib
8 Small Coronary Artery Treated by TAXUS Liberté Registry in Japan Unknown status NCT00955214 Phase 4
9 Balloon Angioplasty Versus Xpert Stent in CLI Patients XXS Study Unknown status NCT00546845 Phase 4
10 Xience/Promus for Long Coronary Lesion Registry Unknown status NCT01147237 Phase 4
11 Paclitaxel-eluting Balloon Angioplasty With Provisional Use of Nitinol Stent Versus Systematic Implantation of Paclitaxel-eluting Stent for the Treatment of Femoropopliteal de Novo Lesions Unknown status NCT01969630 Phase 4
12 Efficacy and Safety of Paclitaxel-eluting Balloon for Treatment of Lesions in Native Small Coronary Arteries Unknown status NCT01903902 Phase 4
13 Test Efficacy of Biodegradable and Permanent Limus-Eluting Stents Unknown status NCT01068106 Phase 4
14 Italian Diffuse/Multivessel Disease ABSORB Prospective Registry: IT-Disappears Unknown status NCT02004730 Phase 4
15 Platelet Function Assessment for Atherothrombotic Patients Unknown status NCT00513149 Phase 4 Clopidogrel
16 Efficacy of Xience/Promus Versus Cypher in rEducing Late Loss After stENTing Unknown status NCT00698607 Phase 4 6-month clopidogrel therapy;12-month clopidogrel therapy
17 Efficacy of Self-Expanding Nitinol S.M.A.R.T CONTROL Stent Versus Life Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease Unknown status NCT01653600 Phase 4
18 BIfurcation Optimal Treatment Strategy With LYMus Eluting Dedicated Bifurcation Versus Convention Stent Randomized Study Unknown status NCT01430364 Phase 4
19 Comparative Phase IV Study: Efficacy And Safety of TiTAN2 Versus COBALT-CHROME Stents- EVIDENCEII Unknown status NCT01918150 Phase 4
20 Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions Unknown status NCT01278186 Phase 4
21 Non-Polymer-Based, Rapamycin-Eluting Stents to Prevent Restenosis Unknown status NCT00152308 Phase 4
22 Drug Eluting Balloon in peripherAl inTErvention for Below-The-Knee Arteries With Freeway and Lutonix Unknown status NCT02279784 Phase 4
23 To Achieve an Early Reendothelialization at the Expense of Low Restenosis: The EREMUS Study Unknown status NCT00870038 Phase 4
24 The 001-DIOR Multicenter Registry Unknown status NCT01375465 Phase 4
25 Clinical Study to Evaluate the Efficacy of Topical Medications Containing Benzoyl Peroxide and Sulfur in the Regression in the Short Time (24 Hours) of Moderate Acne Vulgaris Grade II (Pimples) Unknown status NCT01260571 Phase 4 Benzoyl peroxide and sulfur
26 Local Thrombolytics Before Thrombectomy in STEMI Unknown status NCT01568931 Phase 4 Urokinase;Saline
27 Optical Coherence Tomography (OCT) Evaluation of Re-endothelization: A Comparison of the Intrepide™ Stent Versus Taxus™ Unknown status NCT00914420 Phase 4
28 Impact of Intravascular Ultrasound(IVUS)-Guided Chronic Total Occlusion Intervention With Drug-eluting Stents Unknown status NCT01563952 Phase 4
29 Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
30 Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Trials(OPEN) Unknown status NCT01735227 Phase 4 omeprazole;Pantoprazole
31 Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease Unknown status NCT01418794 Phase 4
32 Safety and Effectiveness of the Coronary Momo Stent Unknown status NCT01535625 Phase 4
33 Comparison of the Everolimus Eluting With the Biolimus A9 Eluting Stent Unknown status NCT01233453 Phase 4
34 A Study to Evaluate Safety and Efficacy of the ExcelTM Sirolimus Eluting Stent With a Biodegradable Polymer Versus Sirolimus Eluting Stent With Non-Biodegradable Polymer in the Treatment of Patients With de Novo Coronary Artery Lesions Unknown status NCT00825773 Phase 4
35 Treatment of Bifurcated Coronary Lesions With Cypher™-Stent Unknown status NCT00288535 Phase 4
36 Multicentre 2x2 Factorial Randomised Study Comparing Tirofiban Versus Abciximab and SES Versus BMS in AMI Unknown status NCT00229515 Phase 4
37 GISSOC II: Sirolimus Eluting Stent Versus Bare Metal Stent in Chronic Total Coronary Occlusions Unknown status NCT00220558 Phase 4
38 Anti-Restenosis After AMI by Erythropoietin Unknown status NCT00423020 Phase 4 Erythropoietin
39 Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome Unknown status NCT02446730 Phase 4 Prasugel;Clopidogrel
40 Comparison of the Efficacy of Paclitaxel-releasing Balloon Catheter System Versus the Everolimus-Eluting Stent System for Treatment of In-Stent Restenosis Lesions - Harmonizing Optimal Strategy for Treatment of In-Stent Restenosis Lesions (The HOST-ISR Tr Unknown status NCT01093300 Phase 4
41 Comparison of Biolimus-eluting Biodegradable Polymer, Everolimus-eluting and Sirolimus-eluting Coronary Stents Unknown status NCT01268371 Phase 4
42 Efficacy of Thrombosuction in Primary Percutaneous Coronary Intervention of Acute Myocardial Infarction Unknown status NCT01156662 Phase 4
43 Comparison of Strut Coverage With OPTIMAX Versus SYNERGY Stents Unknown status NCT02464397 Phase 4
44 Efficacy and Safety of Nano+ Polymer-free Sirolimus-Eluting Stent: A Optical Coherent Tomography Study Unknown status NCT01925027 Phase 4
45 Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05% Completed NCT01893567 Phase 4 Clobex Spray
46 Randomized, Two-arm, Non-inferiority Study Comparing Endeavor-Resolute Stent With Abbot Xience-V Stent Completed NCT00617084 Phase 4
47 NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-eluting Stent Trial Completed NCT01303640 Phase 4
48 Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting Stent Trial Completed NCT01035450 Phase 4
49 Treatment of Bifurcation Lesions by SINGLE STENT and KISSing Balloon Trial Completed NCT00798954 Phase 4
50 A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatment on Facial Acne Lesions Completed NCT02052752 Phase 4 3% Benzoyl Peroxide;3% Benzoyl Peroxide Placebo;Neutrogena Rapid Clear®

Search NIH Clinical Center for Erythema Multiforme

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Erythema Multiforme

Anatomical Context for Erythema Multiforme

The Foundational Model of Anatomy Ontology organs/tissues related to Erythema Multiforme:

19
Skin

MalaCards organs/tissues related to Erythema Multiforme:

41
Lung, Breast, Prostate, Liver, Brain, Skin, Kidney

Publications for Erythema Multiforme

Articles related to Erythema Multiforme:

(show top 50) (show all 650)
# Title Authors Year
1
Recurrent orogenital erythema multiforme and vulval neutrophilic dermatosis. ( 29901227 )
2018
2
A Case of Erythema Multiforme Major Developed after Sequential Use of Two Immune Checkpoint Inhibitors, Nivolumab and Ipilimumab, for Advanced Melanoma: Possible Implication of Synergistic and/or Complementary Immunomodulatory Effects. ( 29515387 )
2018
3
From HSV infection to erythema multiforme through autoimmune crossreactivity. ( 29635075 )
2018
4
Segmental Erythema Multiforme-Like Drug Eruption by Aromatase Inhibitor Anastrozole - First Case Report and another Example of an Immunocompromised District. ( 29483990 )
2018
5
Atypical Still disease with necrotic keratinocytes: A histologic mimicker of erythema multiforme. ( 29693054 )
2018
6
A Large Epidemiological Study Of Erythema Multiforme In France, With Emphasis On Treatment Choices. ( 29957881 )
2018
7
Erythema multiforme after orf virus infection. ( 29766553 )
2018
8
Tularemia-induced erythema multiforme minor in an 11-year-old girl. ( 29582465 )
2018
9
Characteristics of pediatric recurrent erythema multiforme. ( 29231254 )
2018
10
Lenalidomide as an Alternative to Thalidomide for Treatment of Recurrent Erythema Multiforme. ( 29450445 )
2018
11
Pediatric Lip Adhesion Following Bullous Erythema Multiforme and Review of Similar Oral Complications. ( 29463113 )
2018
12
Reactive perforating leprosy, erythema multiforme-like reactions, sweet's syndrome-like reactions as atypical clinical manifestations of Type 2 leprosy reaction. ( 29516895 )
2018
13
Current Perspectives on Erythema Multiforme. ( 29352387 )
2018
14
Stevens-Johnson syndrome/toxic epidermal necrolysis and erythema multiforme drug-related hospitalisations in a national administrative database. ( 29387340 )
2018
15
Clinical and histologic features of Mycoplasma pneumoniae-related erythema multiforme: A single-center series of 33 cases compared with 100 cases induced by other causes. ( 29559400 )
2018
16
Drug-induced oral erythema multiforme: A diagnostic challenge. ( 29363636 )
2018
17
Erythema multiforme as a reaction to imiquimod 5% cream. ( 28329504 )
2017
18
Contact dermatitis caused by Geranium robertianum with erythema multiforme-like reaction. ( 29164698 )
2017
19
Erythema multiforme following pneumococcal vaccination. ( 28352933 )
2017
20
Autoimmune progesterone dermatitis manifesting as mucosal erythema multiforme in the setting of HIV infection. ( 28050592 )
2017
21
Risperidone-induced Erythema Multiforme Minor. ( 29284818 )
2017
22
Erythema multiforme-like reaction resulting from vitamin K<sub>1</sub>oxide (phytomenadione epoxide). ( 29063687 )
2017
23
Erythema multiforme-like lesions in primary cutaneous aggressive cytotoxic epidermotropic CD8+ T-cell lymphoma: A diagnostic and therapeutic challenge. ( 28644551 )
2017
24
Erythema multiforme induced by alendronate sodium in a geriatric patient: A case report and review of the literature. ( 28828163 )
2017
25
New Presentation of Autoimmune Hepatitis with Erythema Multiforme. ( 29059460 )
2017
26
Dermoscopy of erythema multiforme. ( 28217488 )
2017
27
Erythema multiforme triggered by Treponema pallidum infection in an HIV-infected patient. ( 28820345 )
2017
28
Erythema multiforme-like cutaneous lesions in monomorphic epitheliotropic intestinal T-cell lymphoma: a rare case report. ( 27862162 )
2017
29
Erythema Multiforme Caused by Treatment With Topical Imiquimod 5% in a Patient With Gorlin Syndrome. ( 29173871 )
2017
30
Pustular erythema multiforme major associated with atypical pneumonia. ( 28543859 )
2017
31
Erythema multiforme induced by regorafenib. ( 29263999 )
2017
32
Severe sequelae of erythema multiforme: three cases. ( 28710842 )
2017
33
Erosive erythema multiforme of the oral mucosa with acantholysis et circulating autoantibodies. ( 29327773 )
2017
34
Treatment of recurrent erythema multiforme with adalimumab as monotherapy. ( 28280768 )
2017
35
Apremilast for treatment of recurrent erythema multiforme. ( 28329479 )
2017
36
Severe erythema multiforme-type drug eruption controlled by tumor necrosis factor-I+ antagonist: A case study. ( 29285114 )
2017
37
A case of erythema multiforme drug eruption associated with erythrodermic psoriasis induced by sofosbuvir and daclatasvir. ( 27757979 )
2017
38
Erythema Multiforme Following lines of Blaschko. ( 28727601 )
2017
39
A case of erythema multiforme major following administration of ciprofloxacin ophthalmic drops. ( 29469784 )
2017
40
Generalized lichen planus developing at the healed sites of erythema multiforme in a human immunodeficiency virus-seropositive patient. ( 28540867 )
2017
41
Unexpected recalcitrant course of drug-induced erythema multiforme-like eruption and interstitial pneumonia sequentially occurring after nivolumab therapy. ( 28295542 )
2017
42
Erythema multiforme as a complication of vaccination (occupational accident). ( 28715106 )
2017
43
Erythema multiforme triggered by imiquimod 5% cream. ( 28695983 )
2017
44
Differential Diagnosis of Erythema Multiforme in Childhood: A Comment to Siedner-Weintraub et al. ( 28880342 )
2017
45
A first case of erythema multiforme-like contact dermatitis caused by propolis. ( 28872200 )
2017
46
A case of eczema coxsackium with erythema multiforme-like histopathology in a 14-year-old boy with chronic graft-versus-host disease. ( 28203622 )
2017
47
Serum IL-17 in patients with erythema multiforme or Stevens-Johnson syndrome/toxic epidermal necrolysis drug reaction, and correlation with disease severity. ( 28940568 )
2017
48
Erythema, Multiforme ( 29261983 )
2017
49
Erythema multiforme and erythema nodosum lesions with cervical lymphadenopathy. ( 29085725 )
2017
50
Erythema multiforme-like eruption induced by risedronate. ( 29063697 )
2017

Variations for Erythema Multiforme

Expression for Erythema Multiforme

Search GEO for disease gene expression data for Erythema Multiforme.

Pathways for Erythema Multiforme

Pathways related to Erythema Multiforme according to GeneCards Suite gene sharing:

(show all 43)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.5 CCL17 CXCR3 FASLG IFNG IL2 TNF
2
Show member pathways
13.19 FASLG ICAM1 IFNG IL2 TNF
3
Show member pathways
13.12 CCL17 CXCR3 FASLG IL2 TNF
4
Show member pathways
12.67 FASLG GZMB ICAM1 IFNG IL2 TNF
5
Show member pathways
12.64 CD79A IFNG IL2 TNF
6
Show member pathways
12.63 FASLG ICAM1 IFNG IL2 TNF
7 12.31 CD79A FASLG GZMB IFNG IL2 TNF
8
Show member pathways
12.22 ICAM1 IFNG IL2 TNF
9
Show member pathways
12.19 CCL17 IFNG TNF
10
Show member pathways
12.12 IFNG IL2 TNF
11 12.11 FASLG GZMB TNF
12
Show member pathways
12.11 FASLG GZMB ICAM1 IFNG IL2 TNF
13
Show member pathways
12.07 FASLG GZMB TNF
14
Show member pathways
12.06 CCL17 IL2 TNF
15
Show member pathways
12.06 FASLG IFNG TNF
16
Show member pathways
12.04 FASLG IFNG TNF
17 11.96 ICAM1 IFNG TNF
18
Show member pathways
11.93 CCL17 ICAM1 IFNG IL2
19 11.89 ICAM1 IFNG IL2 TNF
20 11.86 FASLG ICAM1 TNF
21 11.86 CD79A IFNG IL2 TNF
22
Show member pathways
11.83 FASLG GZMB IFNG IL2
23 11.74 ICAM1 IFNG TNF
24 11.69 ICAM1 IFNG IL2
25 11.64 IFNG IL2 TNF
26
Show member pathways
11.61 FASLG IFNG IL2 TNF
27
Show member pathways
11.5 ICAM1 IFNG IL2 TNF
28 11.45 ICAM1 IFNG TNF
29 11.43 IFNG IL2 TNF
30 11.41 CCL17 IFNG IL2
31 11.39 FASLG IFNG TNF
32 11.38 FASLG IFNG IL2 TNF
33 11.36 FASLG ICAM1 IFNG
34 11.26 CXCR3 GZMB IFNG IL2 TNF
35 11.21 IFNG IL2
36 11.19 IFNG TNF
37 11.18 IFNG IL2 TNF
38 11.12 IFNG IL2
39 11.1 FASLG ICAM1 IFNG TNF
40 11.08 IFNG IL2
41 11.06 ICAM1 IFNG
42 10.83 ICAM1 TNF
43
Show member pathways
10.81 FASLG GZMB IFNG IL2 TNF

GO Terms for Erythema Multiforme

Cellular components related to Erythema Multiforme according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.63 CCL17 FASLG ICAM1 IFNG IL2 TNF
2 cell surface GO:0009986 9.56 CXCR3 FASLG ICAM1 TNF
3 immunological synapse GO:0001772 9.32 GZMB ICAM1
4 membrane raft GO:0045121 9.26 CD79A FASLG ICAM1 TNF
5 external side of plasma membrane GO:0009897 9.02 CD79A CXCR3 FASLG ICAM1 TNF

Biological processes related to Erythema Multiforme according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.77 CCL17 FASLG IFNG IL2 TNF
2 cytokine-mediated signaling pathway GO:0019221 9.76 FASLG ICAM1 IL2 TNF
3 positive regulation of protein phosphorylation GO:0001934 9.7 IFNG IL2 TNF
4 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.58 FASLG ICAM1
5 extrinsic apoptotic signaling pathway via death domain receptors GO:0008625 9.57 FASLG TNF
6 protein import into nucleus, translocation GO:0000060 9.56 IFNG TNF
7 positive regulation of protein complex assembly GO:0031334 9.55 IFNG TNF
8 negative regulation of myoblast differentiation GO:0045662 9.54 CCL17 TNF
9 positive regulation of osteoclast differentiation GO:0045672 9.51 IFNG TNF
10 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.49 IFNG TNF
11 regulation of regulatory T cell differentiation GO:0045589 9.48 IFNG IL2
12 necroptotic signaling pathway GO:0097527 9.43 FASLG TNF
13 extrinsic apoptotic signaling pathway GO:0097191 9.43 FASLG IFNG TNF
14 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.4 ICAM1 TNF
15 regulation of signaling receptor activity GO:0010469 9.35 CCL17 FASLG IFNG IL2 TNF
16 positive regulation of nitric oxide biosynthetic process GO:0045429 9.33 ICAM1 IFNG TNF
17 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.32 IFNG TNF
18 positive regulation of vitamin D biosynthetic process GO:0060557 8.62 IFNG TNF

Molecular functions related to Erythema Multiforme according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.02 CCL17 FASLG IFNG IL2 TNF
2 tumor necrosis factor receptor binding GO:0005164 8.96 FASLG TNF

Sources for Erythema Multiforme

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....